Hello,
Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news:
- One of healthcare's top investors, Annie Lamont of Oak HC/FT, shares how she stays competitive in a hot market;
- Dr. Fauci says the Omicron variant of COVID-19 is likely not more severe than Delta;
- But Omicron may pose a challenge to Pfizer's vaccines, a new study shows.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @leah_rosenbaum. Let's get to it…

Oak HC/FT's Annie LamontHollis Johnson/Insider
A top VC who's spent 3 decades investing in healthcare shares the new way she's winning venture deals in a record-breaking market

- Annie Lamont, an Oak HC/FT cofounder, has been investing in healthcare companies for three decades.
- Lamont said that to compete with rising valuations, Oak has started creating companies.
- Incubating young companies can help Oak get more favorable terms in later funding rounds, she said.

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases.Photo by Stefani Reynolds-Pool/Getty Images
Fauci says Omicron variant is 'almost certainly' not more severe than Delta

- Omicron is "almost certainly" not more severe than Delta, Dr. Anthony Fauci told AFP on Tuesday.
- Omicron could even result in milder disease than other variants, Fauci added.
- But scientists are still waiting on data to know how well antibodies hold up against the variant.

A health staff member prepares a COVID-19 test at Sydney International Airport on November 28, 2021.James D. Morgan/Getty Images

Omicron may challenge protection from 2 doses of Pfizer's vaccine more than other variants, early lab data suggests
- Pfizer's COVID-19 vaccine may yield substantially fewer antibodies against the Omicron variant.
- The vaccine showed a 40-fold reduction in antibody levels in a study awaiting peer review.
- But Omicron didn't evade vaccine protection completely. The shots may still protect severe disease.
More stories we're reading:
- Omicron's 'wacko' combination of mutations has scientists split over whether it developed in humans or animals (Insider)
- At-home COVID-19 tests may mean that many cases of the disease go unreported (STAT)
- The pitch deck a medical-software startup used to secure $40 million in Series B funding (Insider)
- At her trial, Elizabeth Holmes denies wrongdoing with Theranos (The New York Times)
- Pfizer says 3 of its shots work against Omicron, citing lab tests, but that 2 appear less effective (Insider)
-Leah
Read the original article on Business Insider